Understanding the immune responses to the meningococcal strain-specific vaccine MeNZB measured in studies of infants

Clinical and Vaccine Immunology

Volumn 13, Issue 7, 2006, Pages 797-801

  Ruijne, N ^a   Lea, R A ^a   O'Hallahan, J ^b   Oster, P ^c   Martin, D ^a  

^a INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

^b MINISTRY OF HEALTH   (New Zealand)

^c CHIRON VACCINES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN G; MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN;

ANTIBODY AFFINITY; ARTICLE; BLOOD; CLINICAL TRIAL; HUMAN; IMMUNIZATION; IMMUNOLOGY; INFANT; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; SERUM BACTERICIDAL ACTIVITY; SPECIES DIFFERENCE; TREATMENT OUTCOME;

ANTIBODIES, BACTERIAL; ANTIBODY AFFINITY; BACTERIAL OUTER MEMBRANE PROTEINS; BLOOD BACTERICIDAL ACTIVITY; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; INFANT; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; SPECIES SPECIFICITY; TREATMENT OUTCOME;

EID: 33748074451     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00038-06     Document Type: Article

References (21)

1. Aase, A., E. A. Hoiby, and T. E. Michaelsen. 1998. Opsonophagocytic and bactericidal activity mediated by purified IgG subclass antibodies after vaccination with the Norwegian group B meningococcal vaccine. Scand. J. Immunol. 47:388-396.
2. Aase, A., G. Bjune, E. A. Hoiby, E. Rosenqvist, A. K. Pedersen, and T. E. Michaelsen. 1995. Comparison among opsonic activity, antimeningococcal immunoglobulin G response, and serum bactericidal activity against meningococci in sera from vaccinees after immunization with a serogroup B outer membrane vesicle vaccine. Infect. Immun. 63:3531-3536.
3. de Kleijn, E., L. van Eijndhoven, C. Vermont, B. Kuipers, H. van Dijken, H. Rumke, R. de Groot, L. van Alphen, and G. van der Dobbelsteen. 2001. Serum bactericidal activity and isotype distribution of antibodies in toddlers and schoolchildren after vaccination with RIVM hexavalent PorA vesicle vaccine. Vaccine 20:352-358.
4. Dyet, K., A. Devoy, R. McDowell, and D. Martin. 2005. New Zealand's epidemic of meningococcal disease described using molecular analysis: implications for vaccine delivery. Vaccine 23:2228-2230.
5. Garred, P., T. E. Michaelsen, and A. Aase. 1989. The IgG subclass pattern of complement activation depends on epitope density and antibody and complement concentration. Scand. J. Immunol. 30:379-382.
6. Longworth, L., R. Borrow, D. Goldblatt, P. Balmer, M. Dawson, N. Andrews, E. Miller, and K. Cartwright. 2002. Avidity maturation following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine in UK infants. Vaccine 20:2592-2596.
7. Martin, D., L. McCallum, A. Glennie, N. Ruijne, P. Blatchford, J. O'Hallahan, and P. Oster. 2005. Validation of the serum bactericidal assay for measurement of functional antibodies against group B meningococci associated with vaccine trials. Vaccine 23:2218-2221.
8. Martin, D. R., S. J. Walker, M. G. Baker, and D. R. Lennon. 1998. New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4. J. Infect. Dis. 177:497-500.
9. Martin, D. R., N. Ruijne, L. McCallum, J. O'Hallahan, and P. Oster. 2006. The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin. Vaccine Immunol. 13:486-491.
10. McCloskey, N., M. W. Turner, and D. Goldblatt. 1997. Correlation between the avidity of mouse-human IgG subclass monoclonal antibodies measured by solid-phase elution ELISA and biospecific intraction analysis (BIA). J. Immunol. Methods 205:67-72.
11. Michaelsen, T. E., P. Garred, and A. Aase. 1991. Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration. Eur. J. Immunol. 2:11-16.
12. Naess, L. M., T. Aarvak, A. Aase, F. Oftung, E. A. Hoiby, R. Sandin, and T. E. Michaelsen. 1999. Human IgG subclass responses in relation to serum bactericidal and opsonic activities after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine. Vaccine 17:754-764.
13. O'Hallahan, J., D. Lennon, P. Oster, R. Lane, S. Reid, K. Mulholland, J. Stewart, L. Penney, T. Percival, and D. Martin. 2005. From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal disease. Vaccine 23:2197-2201.
14. Oster, P., D. Lennon, J. O'Hallahan, K. Mulholland, S. Reid, and D. Martin. 2005. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 23:2191-2196.
15. Pollard, A. J., and M. Levin. 2000. Production of low-avidity antibody by infants after infection with serogroup B meningococci. Lancet 356:2065-2066.
16. Pollard, A. J., R. Galassini, E. M. van der Voort, R. Booy, P. Langford, S. Nadel, C. Ison, J. S. Kroll, H. Poolman, and M. Levin. 1999. Humoral immune responses to Neisseria meningitidis in children. Infect. Immun. 67:2441-2451.
17. Richmond, P., R. Borrow, D. Goldblatt, J. Findlow, S. Martin, R. Morris, K. Cartwright, and E. Miller. 2001. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J. Infect. Dis. 183:160-163.
18. Sell, S. 1987. Basic immunology: immune mechanisms in health and disease, p. 217-218. Elsevier Science Publishing Co., Amsterdam, The Netherlands.
19. Sjursen, H., E. Wedege, E. Rosenqvist, A. Naess, A. Halstensen, and R. Matre. 1990. IgG subclass antibodies to serogroup B meningococcal outer membrane antigens following infection and vaccination. APMIS 98:1061-1069.
20. Vermont, C. L., H. H. van Dijken, C. J. P. van Limpt, R. de Groot, L. van Alphen, and G. P. J. M. van del Dobbelsteen. 2002. Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine. Infect. Immun. 70:584-590.
21. Vermont, C. L., H. H. van Dijken, R. de Groot, and G. P. J. M. van den Dobbelstein. 2005. Porin A-specific antibody avidity in patients who are convalescing from meningococcal B disease. Pediatr. Res. 58:1-4.